U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07214987) titled 'PDT For Induction Therapy For Head And Neck Cancer' on Sept. 25.
Brief Summary: This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for patients with CPS-positive locally advanced head and neck squamous cell carcinoma (HNSCC).
Study Start Date: March 09, 2026
Study Type: INTERVENTIONAL
Condition:
Squamous Cell Carcinoma
Head and Neck Cancer Squamous Cell Carcinoma
Head and Neck Cancer
Intervention:
DRUG: Toripalimab-tpzi
Toripalimab-tpzi is a humanized IgG4 monoclonal antibody specific against human PD-1.
DRUG: Cisplatin
C...